检索结果-南通市图书馆

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

人胃癌类器官构建、质量控制与保藏团体标准

中华消化外科杂志 2024年第6期23卷 761-769页

作者：中国抗癌协会苗智峰王振宁不详中国医科大学附属第一医院胃肠肿瘤外科沈阳110001 中国医科大学胃肠肿瘤精准诊疗教育部重点实验室沈阳110001

近年来,类器官技术为肿瘤生物学研究、药物筛选、精准医疗和再生医学等领域提供了革命性的技术平台.与传统的二维细胞系和动物模型相比,源自患者的肿瘤类器官模型在结构和功能上更逼真地模拟了人体内的肿瘤微环境和肿瘤异质性,保留了原... 详细信息

近年来,类器官技术为肿瘤生物学研究、药物筛选、精准医疗和再生医学等领域提供了革命性的技术平台.与传统的二维细胞系和动物模型相比,源自患者的肿瘤类器官模型在结构和功能上更逼真地模拟了人体内的肿瘤微环境和肿瘤异质性,保留了原始肿瘤组织的病理学特征和遗传学信息,成为医学研究人员和临床工作者关注的热点.然而,行业内对于肿瘤类器官的构建及鉴定尚缺乏统一的操作标准,限制了类器官技术在基础研究和临床应用中的广泛推广和应用.因此,为推动类器官技术的规范化和标准化应用,中国抗癌协会联合国内相关领域的专家,制订针对胃癌原发灶和转移灶来源胃癌类器官的培养与质量控制的标准化和可复制的团体标准,旨在为临床工作者和医学研究者提供全面的指导,确保类器官研究的可靠性和可重复性,从而提高研究成果的准确性和应用价值.该团体标准的发布和实施,将为胃癌类器官技术的规范化和广泛应用提供强有力的支持,推动行业的健康、规范发展.随着未来基于胃癌类器官的研究不断深入,该团体标准也将根据最新的研究成果进行定期更新,以持续推动类器官技术在胃癌的基础研究和临床应用中的发展.

关键词：胃肿瘤类器官质量控制团体标准

chinese national clinical practice guidelines on prevention, diagnosis and treatment of early colorectal cancer

在线全文

学校读者我要写书评

暂无评论

中华医学杂志(英文版) 2024年第17期137卷 2024 Aug 6页

作者： Li Jingnan Yao Hongwei Lu Yun Zhang Shutian Zhang Zhongtao society of Digestive Endoscopy of the chinese Medical association Colorectal Surgery Group of the chinese Medical association chinese association of Gastroenterologist & Hepatologist National Clinical Research Center for Digestive Diseases chinese Medical Journal Clinical Practie Guideline Collaborative Department of Gastroenterology Peking Union Medical College Hospital Chinese Academy of Medical Sciences Peking Union Medical College Beijing China Department of General Surgery Beijing Friendship Hospital Capital Medical University National Clinical Research Center for Digestive Diseases Beijing China Department of General Surgery The Affiliated Hospital of Qingdao University Qingdao Shandong China Department of Gastroenterology Beijing Friendship Hospital Capital Medical University National Clinical Research Center for Digestive Disease Beijing China

Background: The incidence and mortality of colorectal cancer (CRC) in China are increasing in recent years. The clarified pathogenesis and detectable precancerous lesions of CRC make it possible to prevent, screen, and diagnose CRC at an early stage. With the development of endoscopic and surgical techniques, the choice of treatment for early CRC is also worth further discussion, and accordingly, a standard follow-up program after treatment needs to be ***: This clinical practice guideline (CPG) was developed following the recommended process of the World Health Organization, adopting Grading of Recommendations Assessment, Development and Evaluation (GRADE) in assessing evidence quality, and using the Evidence to Decision framework to formulate clinical recommendations, thereby minimizing bias and increasing transparency of the CPG development process. We used the Reporting Items for practice Guidelines in HealThcare (RIGHT) statement and Appraisal of Guidelines for Research and Evaluation II (AGREE II) as reporting and conduct guides to ensure the guideline’s completeness and ***: This CPG comprises 46 recommendations concerning prevention, screening, diagnosis, treatment, and surveillance of CRC. In these recommendations, we have indicated protective and risk factors for CRC and made recommendations for chemoprevention. We proposed a suitable screening program for CRC based on the chinese context. We also provided normative statements for the diagnosis, treatment, and surveillance of CRC based on existing clinical evidence and ***: The 46 recommendations in this CPG are formed with consideration for stakeholders’ values and preferences, feasibility, and acceptability. Recommendations are generalizable to resource-limited settings with similar CRC epidemiology pattern as China.

关键词： Colorectal cancer Early detection of cancer Prevention Screening Diagnosis Treatment Follow-up Guideline

子宫颈癌免疫检查点抑制剂临床应用指南(2024年版)

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

中国实用妇科与产科杂志 2024年第7期40卷 712-719页

作者：中国抗癌协会宫颈癌专业委员会周琦龙行涛不详重庆大学附属肿瘤医院妇科肿瘤中心、重庆市卵巢癌专病医学研究中心重庆40003 重庆大学附属肿瘤医院妇科肿瘤中心、重庆市卵巢癌专病医学研究中心重庆400030

子宫颈癌是全球女性第四大常见恶性肿瘤,2020年全球约有60.4万例新确诊病例,34.2万例死亡病例[1]。我国癌症中心发布的全国癌症统计数据报告显示,2022年中国子宫颈癌新发病例估计为15.07万例,死亡例数估计为5.57万例。农村的发病率和死... 详细信息

子宫颈癌是全球女性第四大常见恶性肿瘤,2020年全球约有60.4万例新确诊病例,34.2万例死亡病例[1]。我国癌症中心发布的全国癌症统计数据报告显示,2022年中国子宫颈癌新发病例估计为15.07万例,死亡例数估计为5.57万例。农村的发病率和死亡率均高于城市,且子宫颈癌发病有年轻化趋势[2]。晚期子宫颈癌治愈率低,亟待提高疗效。程序性死亡受体1(programmed death-1,PD-1)及程序性死亡受体配体1(programmed death ligand-1,PD-L1)抑制剂在晚期、复发子宫颈癌中显示了满意疗效。免疫检查点抑制剂(immune checkpoint inhibitors,ICI)通过阻断免疫检查点信号传递解除免疫抑制,恢复T细胞功能,从而有效激活免疫系统并产生抗肿瘤免疫应答杀伤肿瘤细胞。

关键词：子宫颈癌免疫检查点抑制剂指南

chinese national clinical practice guidelines on the prevention,diagnosis,and treatment of early gastric cancer

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

chinese Medical Journal 2024年第8期137卷 887-908页

作者： Peng Li Ziyu Li Enqiang Linghu Jiafu Ji society of Digestive Endoscopy of the chinese Medical association Colorectal Surgery Group of the chinese Medical association chinese association of Gastroenterologists&Hepatologists National Clinical Research Center for Digestive Diseases chinese Medical Journal Clinical Practice Guideline Collaborative Department of Gastroenterology Beijing Friendship HospitalCapital Medical UniversityNational Clinical Research Center for Digestive DiseaseBeijing 100050China Department of Gastrointestinal Surgery Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer Hospital and InstituteBeijing 100142China Department of Gastroenterology and Hepatology the First Medical CenterChinese People’s Liberation Army General HospitalBeijing 100853China 不详

Background:Gastric cancer is one of the most common malignant tumors in the digestive system in *** comprehensive practice guidelines for early gastric cancer in China are currently ***,we created the chinese national clinical practice guideline for the prevention,diagnosis,and treatment of early gastric ***:This clinical practice guideline(CPG)was developed in accordance with the World Health Organization’s recommended process and with the Grading of Recommendations Assessment,Development,and Evaluation(GRADE)in assessing evidence *** used the Evidence to Decision framework to formulate clinical recommendations to minimize bias and increase transparency in the CPG development *** used the Reporting Items for practice Guidelines in HealThcare(RIGHT)statement and the Appraisal of Guidelines for Research and Evaluation II(AGREE II)as reporting and conduct guidelines to ensure completeness and transparency of the ***:This CPG contains 40 recommendations regarding the prevention,screening,diagnosis,treatment,and follow-up of early gastric cancer based on available clinical studies and *** provide recommendations for the timing of Helicobacter pylori eradication,screening populations for early gastric cancer,indications for endoscopic resection and surgical gastrectomy,follow-up interval after treatment,and other ***:This CPG can lead to optimum care for patients and populations by providing up-to-date medical *** intend this CPG for widespread adoption to increase the standard of prevention,screening,diagnosis,treatment,and follow-up of early gastric cancer;thereby,contributing to improving national health care and patient quality of life.

关键词： Early gastric cancer Prevention Screening Diagnosis Treatment Follow-up

影像引导下肿瘤冷冻消融治疗围手术期护理专家共识(2024版)

在线全文

学校读者我要写书评

暂无评论

介入放射学杂志 2024年第10期33卷 1049-1052页

作者：马丽董薪何丽中国抗癌协会肿瘤微创治疗专业委员会中国医药教育协会介入微创治疗专业委员会中国人民解放军总医院第一医学中心

影像引导下肿瘤冷冻消融治疗以其精准、微创、示踪性好、消融范围可控、存在免疫诱导效应等优势获得广泛应用。但在消融过程中存在皮肤冻伤、低体温、冷休克等并发症,严重时甚至可发生急性肾功能衰竭以及死亡。影像引导肿瘤消融治疗的... 详细信息

影像引导下肿瘤冷冻消融治疗以其精准、微创、示踪性好、消融范围可控、存在免疫诱导效应等优势获得广泛应用。但在消融过程中存在皮肤冻伤、低体温、冷休克等并发症,严重时甚至可发生急性肾功能衰竭以及死亡。影像引导肿瘤消融治疗的围手术期护理可防治术中、术后并发症,提升患者围手术期的安全性及舒适度。中国抗癌协会肿瘤微创治疗专业委员会、中国医药教育协会介入微创治疗专业委员会邀请全国介入领域专家共同讨论,制定了该共识,以期在推广的同时获得持续改进。

关键词：肿瘤影像引导冷冻消融护理专家共识

骨改良药物用于恶性肿瘤骨转移治疗的安全性共识(2024版)

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

中华肿瘤杂志 2024年第7期46卷 637-645页

作者：中国医师协会肿瘤医师分会乳腺癌学组中国抗癌协会国际医疗交流分会袁芃徐兵河王雪不详国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院特需医疗部北京100021

骨改良药物是一类缓解因骨转移引起的疼痛、病理性骨折、脊髓压迫、高钙血症等一系列骨相关事件药物的总称,目前包括双膦酸盐和RANKL抑制剂。由于骨改良药物广泛应用,其药物的不良反应逐渐增多,并影响患者的生活质量。中国医师协会肿瘤... 详细信息

骨改良药物是一类缓解因骨转移引起的疼痛、病理性骨折、脊髓压迫、高钙血症等一系列骨相关事件药物的总称,目前包括双膦酸盐和RANKL抑制剂。由于骨改良药物广泛应用,其药物的不良反应逐渐增多,并影响患者的生活质量。中国医师协会肿瘤医师分会乳腺癌学组和中国抗癌协会国际医疗交流分会组织相关专家,基于循证医学证据,聚焦晚期恶性肿瘤骨转移的治疗,探讨骨改良药物不良反应的管理并形成共识。共识在我国2021年版的《骨改良药物安全性管理专家共识》基础上增加了骨改良药物相关颌骨坏死的定义,补充了更多骨改良药物不良反应的文献报道,总结了近年临床医师在实践中对不良反应处理的诊疗经验,最终经过专家组成员深入探讨提出合理建议,以指导临床医师对骨改良药物的安全性管理。

关键词：恶性肿瘤骨转移骨改良药物不良反应专家共识

肝细胞癌伴微血管侵犯诊断和治疗中国专家共识(2024版)

在线全文

学校读者我要写书评

暂无评论

中华消化外科杂志 2024年第2期23卷 153-164页

作者：中国医师协会肝癌专业委员会沈锋程树群孙居仙夏勇不详海军军医大学第三附属医院上海200438

肝细胞癌(以下简称肝癌)是我国常见的恶性肿瘤之一,手术切除是首选的治疗方法,但术后复发转移率高。目前证据表明微血管侵犯(MVI)是导致肝癌复发转移的独立危险因素,但是目前国际上对于MVI的诊断、分型、预测和治疗仍存在较多争议。为... 详细信息

肝细胞癌(以下简称肝癌)是我国常见的恶性肿瘤之一,手术切除是首选的治疗方法,但术后复发转移率高。目前证据表明微血管侵犯(MVI)是导致肝癌复发转移的独立危险因素,但是目前国际上对于MVI的诊断、分型、预测和治疗仍存在较多争议。为更好地指导肝癌伴MVI的诊断和治疗,中国医师协会肝癌专业委员会组织国内相关领域专家,经过多次讨论和修改,形成《肝细胞癌伴微血管侵犯诊断和治疗中国专家共识(2024版)》,以供国内同行参考。

关键词：肝细胞癌微血管侵犯诊断治疗共识

chinese national clinical practice guideline on diagnosis and treatment of biliary tract cancers

在线全文

学校读者我要写书评

暂无评论

中华医学杂志(英文版) 2024年第19期137卷 2024 Sep 4页

作者： Wang Xu’an Bai Yongrui Chai Ningli Li Yexiong Linghu Enqiang Wang Liwei Liu Yingbin society of Hepato-pancreatobiliary Surgery of chinese Research Hospital association society of Digestive Endoscopy of the chinese Medical association chinese Medical Journal Clinical Practice Guideline Collaborative Department of Biliary and Pancreatic Surgery Renji Hospital Shanghai Jiao Tong University School of Medicine State Key Laboratory of Systems Medicine for cancers Shanghai Cancer Institute Shanghai Key Laboratory for cancer Systems Regulation and Clinical Translation Shanghai China Department of Radiation Oncology Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai China Department of Gastroenterology and Hepatology the First Medical Center Chinese People’s Liberation Army General Hospital Beijing China State Key Laboratory of Molecular Oncology and Department of Radiation Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) Beijing China State Key Laboratory of Oncogenes and Related Genes Shanghai Cancer Institute Department of Oncology Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai China

Background: Biliary tract carcinoma (BTC) is relatively rare and comprises a spectrum of invasive tumors arising from the biliary tree. The prognosis is extremely poor. The incidence of BTC is relatively high in Asian countries, and a high number of cases are diagnosed annually in China owing to the large population. Therefore, it is necessary to clarify the epidemiology and high-risk factors for BTC in China. The signs associated with BTC are complex, often require collaborative treatment from surgeons, endoscopists, oncologists, and radiation therapists. Thus, it is necessary to develop a comprehensive chinese guideline for ***: This clinical practice guideline (CPG) was developed following the process recommended by the World Health Organization. The Grading of Recommendations Assessment, Development, and Evaluation approach was used to assess the certainty of evidence and make recommendations. The full CPG report was reviewed by external guideline methodologists and clinicians with no direct involvement in the development of this CPG. Two guideline reporting checklists have been adhered to: Appraisal of Guidelines for Research and Evaluation (AGREE) and Reporting Items for practice Guidelines in Healthcare (RIGHT).Results: The guideline development group, which comprised 85 multidisciplinary clinical experts across China. After a controversies conference, 17 clinical questions concerning the prevention, diagnosis, and treatment of BTC were proposed. Additionally, detailed descriptions of the surgical principles, perioperative management, chemotherapy, immunotherapy, targeted therapy, radiotherapy, and endoscopic management were ***: The guideline development group created a comprehensive chinese guideline for the diagnosis and treatment of BTC, covering various aspects of epidemiology, diagnosis, and treatment. The 17 clinical questions have important reference value for the management of BTC.

关键词： Biliary tract carcinoma Etiology Diagnosis Treatment Surgery

妇科恶性肿瘤抗体偶联药物临床应用指南(2024年版)

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

中国实用妇科与产科杂志 2024年第5期40卷 516-525页

作者：中国抗癌协会宫颈癌专业委员会周晖张丙忠林仲秋不详中山大学孙逸仙纪念医院妇科肿瘤专科广东广州510120

1引言妇科恶性肿瘤严重威胁女性生命健康。尤其复发性肿瘤,受限于传统治疗手段,预后极差。抗体药物偶联物(antibody-drug conjugate,ADC)由抗体、连接子和细胞毒性药物组成。单克隆抗体作为载体将细胞毒性药物以靶向的方式高效地运输至... 详细信息

1引言妇科恶性肿瘤严重威胁女性生命健康。尤其复发性肿瘤,受限于传统治疗手段,预后极差。抗体药物偶联物(antibody-drug conjugate,ADC)由抗体、连接子和细胞毒性药物组成。单克隆抗体作为载体将细胞毒性药物以靶向的方式高效地运输至目标肿瘤细胞中,有效地提高了抗肿瘤治疗的效益风险比。此类药物随着靶点和适应证的不断扩展,逐渐成为恶性肿瘤综合治疗的重要手段之一。目前国内尚未广泛开展ADC药物用于妇科肿瘤的治疗。中国抗癌协会宫颈癌专业委员会组织专家对现有妇科肿瘤ADC药物临床应用的证据进行总结,在我国临床实践特定背景下制订了本指南,以指导ADC药物的规范应用和科学管理,提高妇科恶性肿瘤规范化治疗水平。

关键词：妇科恶性肿瘤抗体偶联药物指南